DiaKine Therapeutics Inc.
This article was originally published in Start Up
Executive Summary
DiaKine Therapeutics. is a biopharmaceutical company focused on novel treatments for type 1 and type 2 diabetes. The company is developing a molecule called lisofylline and related analogs to modulate the inflammatory response that triggers the destruction of insulin-producing beta cells in the pancreas.